Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Medronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.44 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.32 |
| ▸ | CA4 known ✓ | P22748 | 2/20 | 0.32 |
| ▸ | TYMS known ✓ | P04818 | 1/20 | 0.32 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.31 |
| ▸ | FDPS known ✓ | P14324 | 1/20 | 0.31 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | OTC | P00480 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medronic Acid SCHEMBL2638879 | 0.86 | SLC34A1 (0.41) | SLC34A1KDM4EMMP2THRBMAPK1 | |
| Medronic Acid SCHEMBL7929832 | 0.79 | SLC34A1 (0.50) | SLC34A1KDM4EMMP2THRBMAPK1 | |
| SCHEMBL7163767 | 0.74 | — | — | |
| SCHEMBL27943900 | 0.74 | — | — | |
| Phosphoric Acid SCHEMBL736578 | 0.74 | SLC34A1 (0.64) | SLC34A1KDM4EMMP2THRBMAPK1 | |
| Phosphoric Acid SCHEMBL11660 | 0.74 | — | — | |
| Phosphoric Acid SCHEMBL11283215 | 0.74 | SLC34A1 (0.80) | SLC34A1KDM4EMMP2THRBMAPK1 | |
| Phosphoric Acid SCHEMBL1330805 | 0.74 | — | — | |
| Phosphoric Acid SCHEMBL31035931 | 0.74 | SLC34A1 (0.80) | SLC34A1KDM4EMMP2THRBMAPK1 | |
| Phosphoric Acid SCHEMBL184098 | 0.74 | SLC34A1 (0.80) | SLC34A1KDM4EMMP2THRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 743 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878984-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2018-01-30 | — | — | US | claimed |
| US-20140378503-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY | 2014-12-25 | — | — | US | claimed |
| US-8829025-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2014-09-09 | — | — | US | claimed |
| US-20130225634-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2013-08-29 | — | — | US | claimed |
| US-20100303719-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2010-12-02 | — | — | US | claimed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | claimed |
| WO-2009089537-A2 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2009-07-16 | — | — | WO | claimed |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250312364-A1 | METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2025-10-09 | — | — | US | disclosed |
| US-12403177-B2 | Silk-based product formulations and methods of use | COCOON BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12350375-B2 | Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy | LEUKOCARE AG (DE) | 2025-07-08 | — | — | US | disclosed |
| WO-2025049959-A9 | GENE EDITING SYSTEMS, COMPOSITIONS, AND METHODS FOR TREATMENT OF VEXAS SYNDROME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-5225182-A | For specific organ delivery | SHARMA YASH P (US) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378503-A1 | ANTI-CANCER COMPOUNDS | TP53, MKI67, MYC | THRB 4780/4885CA1 3688/4885CA4 1202/4885 |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | RNMT, NSUN2, AMPD1 | THRB 1762/4885CA1 4629/4885CA4 4853/4885 |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | ATP5F1A, ATP5MF, MT-ATP6 | THRB 4644/4885CA1 2508/4885CA4 3178/4885 |
| US-20100303719-A1 | ANTI-CANCER COMPOUNDS | TP53, MKI67, MYC | THRB 4780/4885CA1 3688/4885CA4 1202/4885 |
| US-20130225634-A1 | ANTI-CANCER COMPOUNDS | TP53, MKI67, MYC | THRB 4780/4885CA1 3688/4885CA4 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.